Publications by authors named "Pierre Colonna"

Claim this Profile
F
Formation of Substituted Benzocyclobutenes Starting from Donor-Acceptor Cyclopropanes.
Bohdan Biletskyi, Maxime Dousset, Pierre Colonna, Virginie Héran, Yannick Carissan

J Org Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deuteration and Tritiation of Pharmaceuticals by Non-Directed Palladium-Catalyzed C-H Activation in Heavy and Super-Heavy Water.
Chitrala Teja, Simon Kolb, Pierre Colonna, Jagrit Grover, Sébastien Garcia-Argote

Angew Chem Int Ed Engl· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Au(I)-Catalyzed Regioselective Hydrogen Isotope Labeling of Indoles.
Pierre Milcendeau, Pierre Colonna, Mohammed Ramdani, Sébastien Garcia-Argote, Nicolas Glinsky-Olivier

Org Lett· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small rings in the bigger picture: ring expansion of three- and four-membered rings to access larger all-carbon cyclic systems.
Bohdan Biletskyi, Pierre Colonna, Kévin Masson, Jean-Luc Parrain, Laurent Commeiras

Chem Soc Rev· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the Quality of Host Country Ethical Oversight of International Research: The Use of a Collaborative 'Pre-Review' Mechanism for a Study of Fexinidazole for Human African Trypanosomiasis.
Carl H Coleman, Chantal Ardiot, Séverine Blesson, Yves Bonnin, Francois Bompart, Pierre Colonna

Dev World Bioeth· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
Nina Arakelyan, Jean-Philippe Jais, Cécile Tomowiack, Philippe Colombat, Christian Berthou, Pierre Colonna

Leuk Lymphoma· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
Nina Arakelyan, Jean-Philippe Jais, Vincent Delwail, Josette Brière, Marie-Pierre Moles-Moreau, Pierre Colonna

Cancer· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Nina Arakelyan, Christian Berthou, Bernard Desablens, Sophie de Guibert, Vincent Delwail, Pierre Colonna

Cancer· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Delphine Sénécal, Jean-Philippe Jais, Bernard Desablens, Christian Berthou, Philippe Casassus, Pierre Colonna

Cancer· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas.
Delphine Maucort-Boulch, Malika Djeridane, Pascal Roy, Benjamin Riche, Pierre Colonna

Cancer· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
Pierre Feugier, Eric Labouyrie, Malika Djeridane, Arash Jenabian, Viviane Dubruille, Pierre Colonna

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
Christine le Maignan, Bernard Desablens, Vincent Delwail, Mahmoud Dib, Christian Berthou, Pierre Colonna

Blood· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Malika Djeridane, Stéphane Oudard, Martine Escoffre-Barbe, Laurence Lacotte-Thierry, Bernard Desablens, Pierre Colonna

Cancer· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Vincent Delwail, Jean-Philippe Jais, Pierre Colonna, Jean-Marie Andrieu

Br J Haematol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis